A Study of NST-6179 in Adult Subjects With Intestinal Failure-Associated Liver Disease (IFALD).
Trial ID or NCT#
Status
RECRUITING
Purpose
This is a phase 2a, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NST-6179 in adult subjects with intestinal failure-associated liver disease (IFALD) receiving parenteral nutrition (PN). The study will be conducted in 2 sequential parts. Up to 36 adult subjects diagnosed with IFALD will be enrolled in the study, of which 18 subjects will be enrolled in each of the 2 parts and randomized (2:1) to receive NST-6179 (N=12/part) or matched placebo (N=6/part). Subjects in Part A will receive once daily (QD) oral administration of 800 mg (32 mL solution) NST-6179 or placebo for 4 weeks. The NST-6179 dose for Part B is planned to be 1200 mg QD for 12 weeks. Actual dose, however, will be determined during the safety review meeting.
Official Title
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NST-6179 in Adult Subjects With Intestinal Failure-Associated Liver Disease (IFALD)
Eligibility Criteria
- * Adult persons aged 18 years or older at the time of informed consent.* Minimum of 6 months on Parenteral supplementation.* Established clinical diagnosis of IFALD based on a persistent elevation of
- 1. liver enzymes (ALP, AST, ALT, or GGT ≥1.5 × upper limit of normal \[ULN\]) for ≥6 months and/or 2. total bilirubin \> ULN for ≥6 months.* Laboratory parameters consistent with stable liver disease without cirrhosis as defined by:
- 1. ALT and AST \<5 × ULN; 2. Total bilirubin ≤2.0 mg/dL in the absence of Gilbert's Syndrome. 3. Serum albumin ≥3 g/dL; 4. International normalized ratio (INR) ≤1.3 in the absence of anticoagulant therapy; 5. Platelet count ≥120,000/mm3.
- Key
- * Clinical, laboratory, imaging, or histopathologic evidence of other causes of acute or chronic liver disease, including autoimmune, viral, metabolic, or alcoholic liver disease.* Clinical evidence of compensated or decompensated hepatic cirrhosis as assessed by historical liver histology, ultrasound-based and/or signs and symptoms of hepatic decompensation (including, but not limited to, jaundice, ascites, variceal hemorrhage, and/or hepatic encephalopathy).* Presence of hepatic impairment, end-stage liver disease, and/or a model for end-stage liver disease (MELD) score \>12.* Transient elastography read \>20.0 kPA within 3 months prior to or during the Screening Period.* Estimated glomerular filtration rate \<45 mL/min based on the 2021 CKD-EPI creatinine equation.* Poor nutritional status defined as body mass index (BMI) \<17 kg/m2.
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Andrew Bonham, MD
View on ClinicalTrials.gov
